Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Rx Regs Will Be Final By February, CMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Internal deadline would give potential drug plan sponsors time to consider their role in Medicare and prepare bids, CMS official tells FDLI teleconference. CMS will screen potential bidders for Part D criteria through request for proposals process.

You may also be interested in...



Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman

CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.

Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman

CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.

Medicare Rx Implementing Regs Open For Comment Until October

Proposed rules for Title I (Part D drug benefit) and Title II (Medicare Advantage) of the Medicare Modernization Act are unveiled at an HHS press conference. Final regs will be done by early 2005, "if not sooner," CMS Administrator McClellan says.

Related Content

Topics

UsernamePublicRestriction

Register

PS060783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel